Oxford BioMedica Announces Successful Completion of ProSavin Phase I/II Study in Parkinson's Disease
Study meets primary endpoint: ProSavin is safe, well-tolerated and mediates long-term improvement of motor function
19-Apr-2012 -
Oxford BioMedica plc announces that it has successfully completed a Phase I/II study to assess the safety, efficacy and dose evaluation of ProSavin® in patients with mid-stage Parkinson’s disease (PD) who are experiencing reduced benefit on L-DOPA "equivalent" therapy.
The study evaluated three ...
Oxford BioMedica
Parkinson's disease